DK2143429T5 - Anvendelse af cilastatin til reduktion af nephrotoksicitet af forskellige forbindelser - Google Patents

Anvendelse af cilastatin til reduktion af nephrotoksicitet af forskellige forbindelser

Info

Publication number
DK2143429T5
DK2143429T5 DK09164710.7T DK09164710T DK2143429T5 DK 2143429 T5 DK2143429 T5 DK 2143429T5 DK 09164710 T DK09164710 T DK 09164710T DK 2143429 T5 DK2143429 T5 DK 2143429T5
Authority
DK
Denmark
Prior art keywords
cilastatin
various compounds
reduce nephrotoxicity
nephrotoxicity
reduce
Prior art date
Application number
DK09164710.7T
Other languages
English (en)
Other versions
DK2143429T3 (da
Inventor
Jorge Alberto Tejedor
Fernandez Alberto Lazaro
Paez Sonia Camano
Redondo Ana María Torres
Manero José Antonio Lazaro
Barba Manuela Castilla
Lucas Collantes María Del Carmen De
Original Assignee
Fundacion Para La Investigacion Biomedica Del Hospital Gregorio Mara On
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fundacion Para La Investigacion Biomedica Del Hospital Gregorio Mara On filed Critical Fundacion Para La Investigacion Biomedica Del Hospital Gregorio Mara On
Publication of DK2143429T3 publication Critical patent/DK2143429T3/da
Application granted granted Critical
Publication of DK2143429T5 publication Critical patent/DK2143429T5/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/02Halogenated hydrocarbons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/045Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/28Compounds containing heavy metals
    • A61K31/282Platinum compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/662Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/7036Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • A61K33/243Platinum; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/04X-ray contrast preparations
    • A61K49/0433X-ray contrast preparations containing an organic halogenated X-ray contrast-enhancing agent
    • A61K49/0438Organic X-ray contrast-enhancing agent comprising an iodinated group or an iodine atom, e.g. iopamidol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK09164710.7T 2008-07-11 2009-07-07 Anvendelse af cilastatin til reduktion af nephrotoksicitet af forskellige forbindelser DK2143429T5 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/ES2008/070137 WO2010004060A1 (es) 2008-07-11 2008-07-11 Uso de la cilastatina para reducir la nefrotoxicidad de distintos compuestos

Publications (2)

Publication Number Publication Date
DK2143429T3 DK2143429T3 (da) 2014-02-24
DK2143429T5 true DK2143429T5 (da) 2014-06-30

Family

ID=41131665

Family Applications (1)

Application Number Title Priority Date Filing Date
DK09164710.7T DK2143429T5 (da) 2008-07-11 2009-07-07 Anvendelse af cilastatin til reduktion af nephrotoksicitet af forskellige forbindelser

Country Status (7)

Country Link
US (3) US9216185B2 (da)
EP (1) EP2143429B1 (da)
DK (1) DK2143429T5 (da)
ES (1) ES2451715T3 (da)
PL (1) PL2143429T4 (da)
PT (1) PT2143429E (da)
WO (1) WO2010004060A1 (da)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2726789A1 (en) * 2000-02-05 2001-11-08 Theravance, Inc. Cyclodextrin containing glycopeptide antibiotic compositions
WO2015111666A1 (ja) 2014-01-24 2015-07-30 味の素株式会社 メガリン拮抗剤
IL305285A (en) 2015-08-11 2023-10-01 Arch Biopartners Inc DPEP-1 binding compositions and methods of use
KR101913326B1 (ko) * 2016-03-29 2018-10-30 순천향대학교 산학협력단 실라스타틴을 포함하는, 신장 허혈 재관류 손상의 예방 또는 치료용 약학적 조성물
AU2017281744B2 (en) * 2016-06-24 2022-10-27 Fundación Para La Investigación Biomédica Del Hospital Gregorio Marañón Cilastatin for use in the treatment of sepsis
JP6548803B1 (ja) * 2018-04-27 2019-07-24 国立大学法人 新潟大学 腎障害の抑制におけるシラスタチンの利用
AU2020363688A1 (en) * 2019-10-12 2022-04-21 Farsight Medical Technology (Shanghai) Co., Ltd. Treatment and prevention of nephrotoxin-induced kidney injuries
CN116472037A (zh) * 2021-03-12 2023-07-21 国立大学法人新潟大学 由溶血反应诱发的肾损伤的抑制
EP4230200B1 (en) * 2021-03-12 2025-06-11 Niigata University Agent for inhibiting renal damage induced by rhabdomyolysis
CN113469105A (zh) * 2021-07-15 2021-10-01 恒大恒驰新能源汽车研究院(上海)有限公司 监控周边车辆的方法及装置、计算机可读存储介质
WO2025097170A1 (en) * 2023-11-02 2025-05-08 Proletariat Therapeutics, Inc. A method of minimizing or eliminating nephrotoxicity in patients undergoing treatment with antimicrobial or anticancer drugs
WO2025093926A1 (en) * 2023-11-02 2025-05-08 Saito Akihiko A method of minimizing or eliminating nephrotoxicity in patients undergoing cisplatin-based chemotherapy via sequential administration of a protective agent followed by a toxic agent

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997037649A1 (en) * 1996-04-04 1997-10-16 Merck & Co., Inc. Method of reducing nephrotoxicity
US20070082858A1 (en) * 2004-12-21 2007-04-12 Oregon Health & Science University Methods and compositions for the prevention of toxic side effects of aminoglycoside medications
JP2009535410A (ja) * 2006-05-02 2009-10-01 シーエルエフ メディカル テクノロジー アクセラレーション プログラム インコーポレイテッド ピロロキノリンキノンおよびその使用

Also Published As

Publication number Publication date
PL2143429T3 (pl) 2014-07-31
EP2143429B1 (en) 2013-11-20
DK2143429T3 (da) 2014-02-24
US9216185B2 (en) 2015-12-22
US9522128B2 (en) 2016-12-20
EP2143429A1 (en) 2010-01-13
ES2451715T3 (es) 2014-03-28
US9757349B2 (en) 2017-09-12
US20160136121A1 (en) 2016-05-19
US20170035718A1 (en) 2017-02-09
PT2143429E (pt) 2014-03-27
PL2143429T4 (pl) 2014-07-31
WO2010004060A1 (es) 2010-01-14
US20110165264A1 (en) 2011-07-07

Similar Documents

Publication Publication Date Title
DK2143429T5 (da) Anvendelse af cilastatin til reduktion af nephrotoksicitet af forskellige forbindelser
CY2020033I2 (el) Νεοι ρυθμιστες υποδοχεων φωσφορικης σφιγγοσινης
DK2271219T3 (da) Anvendelse af dithiin-tetracarboximider til bekæmpelse af fytopatogene svampe
DK2449057T3 (da) Fremgangsmåde til omdannelse af lignocellulosematerialer til anvendelige kemikalier
DK2379532T3 (da) Forbindelser, som er egnet til hæmning af chk1
DK2262836T3 (da) Antistof mod CSF-1R
DK2310046T3 (da) Hidtil ukendte adjuvanssammensætninger
BRPI0812630A2 (pt) de compostos funcionais a um substrato
DK2288375T3 (da) Pegylerede insulin-lispro-forbindelser
DK3226459T3 (da) Udveksling af parametre relateret til måleperioder
BRPI0920707A2 (pt) compostos
DK2242759T3 (da) Forbindelser
PT2260053E (pt) Análogos de oxitocina
SMT201400023B (it) Analoghi di buprenorfina
DK2755481T3 (da) Anvendelse af alginatoligomerer til at forøge virkningerne af svampemidler
EP2575790A4 (en) STABILIZED CHEMICAL COMPOSITION
DK2593449T3 (da) Fremgangsmåde til syntese af benzothiadiazolforbindelse
DK2346509T3 (da) Inhalation af levofloxacin til at reducere lungeinflammation
DK2375786T3 (da) System til programmering af specielle funktionsknapper til anvendelse tilhørehjælpsanordninger
DK2323972T3 (da) C7-fluor-substituerede tetracylinforbindelser
DK2358714T3 (da) Alkylcyclohexylethere af dihydrotetraazabenzoazulener
EP2349335A4 (en) LEVETIRACETAM IMMUNOASSAYS
BRPI0916432A2 (pt) compostos
DK2117564T3 (da) Anvendelse af chitosaner til forøgelse af neglevæksthastigheden
DK2424538T3 (da) Anvendelse af allopurinol til behandling af hånd-fod-hudreaktion